Evaluating a practice in radiation oncology: a guide for junior physicians #RadOnc Thread 🧵

From skepticism to evidence 📊 50% improved >5 VAS points 💊 40% cut analgesics ⚠️ 0 toxicities Low-dose RT works for painful musculoskeletical disorders. Period. #ASTRO2025 #ASTRO25 #LDRT Beatriz Álvarez RadioterapiaHM HM HOSPITALES

Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇 bit.ly/BestOfASTRO25

Baseball SBRT: getting your fix in 5 innings or less so you have more time at #ASTRO25

🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. Daniel E Spratt #ASTRO25 #RadOnc

🧪 The Clinical Trials spotlight at #ASTRO25 featured some of the most important work happening right now in GU oncology, with data that could shape practice for years to come. NRG/RTOG-0924: At 10 years, whole pelvic RT (compared to prostate only RT) did not improve OS, PCSS,

Great job Dr. Wells!

Congrats to Georgetown MS-3 Nikita Gupta on her stellar presentation! She is on the challenging MD/MBA track. Her future is bright! #ASTRO25

📢 NRGGU005 Phase III: 698 pts with intermediate-risk #ProstateCancer RCT; SBRT (n=353) vs M-IMRT (n=345) ✅ SBRT → better bowel HRQOL (MCID 35% vs 44%, p=0.03) ⚖️No diff in urinary HRQOL; EPIC continence favours SBRT ❌futile for DFS; IMRT had ⬇️3-yr biochemical failure (4.2%

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

Bad lighting, great company 😉 Had such a BLAST at Georgetown Rad Onc happy hour last night at Dirty Habit! #astro25

Dr. Nitika Paudel, MD.PhD at #DCLung25 discusses evolution of care for unresectable NSCLC. Defining resectability and operability in a multi-disciplinary setting is the key. After chemoradiation - immunotherapy (durvalumab) or, if #EGFR, targeted therapy (osimertinib) improving outcomes

High-yield paper summarizing the MSKCC experience of whole versus “partial larynx” IMRT for stage I-II glottic larynx squamous cell carcinoma. This effort brings up several important points. All patients were treated with IMRT, with the PTV of partial larynx = GTV+ 5 mm +

📢 PACIFIC-2 is OUT: Simultaneous Durvalumab & Chemoradiation in Stage III NSCLC ⚠️A lot to learn from this (negative) trial in an unselected patient population⚠️ 🙏 for open access OncoAlert #lcsm #radonc #immunotherapy #precisiononcology ascopubs.org/doi/10.1200/JC…

📣 #ESMO25: NORTHSTAR RCT @YasirElaminMD; n=120 EGFR-mut #lungcancer osimertinib +/- LCT (68% #radiotherapy) ⬆️ 12-month PFS rate: 72% vs 54% ⬆️ PFS (25.3 vs 17.5 mo; HR 0.66; P=0.025) 😳 really not “oligo” population! ✅Grade ≥3 AEs: 29% (LCT arm) vs 22% (control) #radonc

Grateful to give an oral presentation on our MedStar Georgetown ongoing study on real-time tumor motion vs 4D-CT predictions on lung SBRT at ECOG-ACRIN Cancer Research Group fall 2025! Honored to receive the Travel Grant from the ECOG-ACRIN Radiation Oncology Committee! #RadOnc #SBRT #CyberKnife

🔥 🚨 MEDICAL STUDENT SPOTLIGHT 🚀 Julia Trettin (M4, LSU Health Sciences) just completed her 4-week sub-I rotation with us with a fabulous case-based presentation on clear cell sarcoma management!☢️ Great job Julia!

Brian F. Chapin Himanshu Nagar Amar Kishan 4/n If WW in IR and AM in GG2 are not safe, then what about AS in GG2? Sunnybrook data shows that this still is not very safe with 15 year mets risk of 16% in their historical data published. Note that almost all mets events occur around or beyond 10 years. Dr. Andrew Loblaw

Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials - PubMed pubmed.ncbi.nlm.nih.gov/40447512/

Autumn looks good on you, DC !